Adaptimmune Therapeutics plc Share Price
Stocks
ADAPY
US00653A1079
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0389 USD | -5.12% |
|
-2.75% | +49.62% |
| 19/05 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 17/11 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Market Cap | 1.09Cr 95.28L 87.83L 82.23L 1.54Cr 102.51Cr 1.57Cr 11Cr 4.08Cr 51Cr 4.08Cr 3.99Cr 175.68Cr | P/E 2024 |
-1.8x | P/E 2025 | 0.33x |
|---|---|---|---|---|---|
| Enterprise Value | -10.02L -9L -8L -8L -14.22L -9.45Cr -14.51L -97.32L -37.66L -4.67Cr -37.62L -36.8L -16Cr | EV / Sales 2024 |
0.34x | EV / Sales 2025 | -0.84x |
| Free-Float |
14.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -5.12% | ||
| 1 week | -2.75% | ||
| Current month | +537.70% | ||
| 1 month | +327.47% | ||
| 3 months | +159.33% | ||
| 6 months | +39.93% | ||
| Current year | +49.62% |
| 1 week | 0.02 |  | 0.04 |
| 1 month | 0.01 | | 0.04 |
| Current year | 0 | | 0.04 |
| 1 year | 0 | | 0.36 |
| 3 years | 0 | | 2.05 |
| 5 years | 0 | | 6.86 |
| 10 years | 0 | | 14.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Hill
CEO | Chief Executive Officer | 46 | 14/11/2025 |
Juli P. Miller
IRC | Investor Relations Contact | - | 01/08/2016 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Alleva
CHM | Chairman | 76 | 14/11/2025 |
Garry Menzel
BRD | Director/Board Member | 61 | 01/06/2023 |
Christopher Hill
BRD | Director/Board Member | 46 | 14/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/25/02 | Sell | Chief Financial Officer | 96,000 | 0.0060% | ||
| 28/25/28 | Sell | Compliance Officer | 2,07,000 | 0.0130% | ||
| 15/25/15 | NEA Management Co. LLC
| Sell | Company | 1,95,00,000 | 7.3571% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.12% | -2.75% | -83.94% | -95.76% | 1.09Cr | |
| +2.19% | +3.47% | +21.64% | -19.20% | 6.31TCr | |
| +0.74% | +3.52% | +53.14% | +219.37% | 5.56TCr | |
| -3.10% | +34.30% | +34.30% | +34.30% | 4.16TCr | |
| -2.36% | +6.28% | -51.83% | -59.27% | 3.9TCr | |
| +5.34% | +6.63% | +67.79% | -24.37% | 2.98TCr | |
| +10.08% | +11.33% | +139.91% | -45.13% | 2.37TCr | |
| +5.27% | +8.65% | +59.06% | +78.95% | 2.15TCr | |
| -1.25% | -1.31% | -8.80% | +146.80% | 1.69TCr | |
| -0.81% | +4.81% | +67.70% | +124.13% | 1.67TCr | |
| Average | +1.09% | +3.21% | +29.90% | +35.98% | 3.08TCr | |
| Weighted average by Cap. | +1.41% | +3.29% | +36.75% | +47.27% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 18Cr 16Cr 14Cr 13Cr 25Cr 1.68TCr 26Cr 172.94Cr 67Cr 830.01Cr 67Cr 65Cr 2.88TCr | 59.24L 51.94L 47.88L 44.82L 84.05L 56Cr 85.8L 5.75Cr 2.23Cr 28Cr 2.22Cr 2.18Cr 96Cr |
| Net income | -7.08Cr -6.21Cr -5.72Cr -5.36Cr -10Cr -668.01Cr -10Cr -69Cr -27Cr -330.14Cr -27Cr -26Cr -1.14TCr | 2.52Cr 2.21Cr 2.04Cr 1.91Cr 3.58Cr 237.77Cr 3.65Cr 24Cr 9.47Cr 117.51Cr 9.46Cr 9.26Cr 407.49Cr |
| Net Debt | -7.74Cr -6.79Cr -6.26Cr -5.86Cr -11Cr -730.1Cr -11Cr -75Cr -29Cr -360.83Cr -29Cr -28Cr -1.25TCr | -1.19Cr -1.04Cr -95.93L -89.81L -1.68Cr -111.96Cr -1.72Cr -12Cr -4.46Cr -55Cr -4.46Cr -4.36Cr -191.88Cr |
Employees
272
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/26/26 | $0.0389 | -5.12% | 3,80,261 |
| 25/26/25 | $0.0410 | +13.89% | 6,76,443 |
| 24/26/24 | $0.0360 | +6.82% | 4,52,328 |
| 23/26/23 | $0.0337 | -15.75% | 1,37,766 |
| 22/26/22 | $0.0400 | 0.00% | 2,41,604 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADAPY Stock
Select your edition
All financial news and data tailored to specific country editions
